Suppression of autoimmune disease in NZB/W F1 mice by treatment with the novel immunomodulator BTS 63155.
Autoimmune disease in NZB/W F1 mice was treated from 23 weeks of age with the novel immunomodulator BTS 63155 and, for comparative purposes, the established immunosuppressive agent cyclosporin A. Both drugs significantly improved survival compared with untreated controls. Lupus nephritis was also significantly reduced in the drug-treated groups, and this was related to reduced glomerular deposition of IgG. Autoantibody (ANA) levels were lowered by treatment with cyclosporin A, but not by BTS 63155. This latter finding may indicate a different mode of action for the two drugs. In a long term study, neither drug effected a complete cure, as autoimmune disease recurred on withdrawal of drug treatment.
Appleby
P
P
Boots Pharmaceuticals Research Department, Boots Company PLC, Nottingham, UK.
Telford
G
G
Naylor
G B
GB
D000818:Animals; D000974:Antibodies, Antinuclear / Q000097:blood; D001327:Autoimmune Diseases / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D007074:Immunoglobulin G / Q000032:analysis; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007668:Kidney / Q000276:immunology / Q000473:pathology; D008297:Male; D051379:Mice; D008814:Mice, Inbred NZB; D011507:Proteinuria / Q000517:prevention & control; D011720:Pyrazoles
D000974:Antibodies, Antinuclear; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D011720:Pyrazoles; C083196:BTS 63155; D016572:Cyclosporine